Alto Neuroscience’s (ANRO) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a report released on Thursday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

Several other research analysts have also weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Wedbush raised their target price on shares of Alto Neuroscience from $13.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, March 17th. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Robert W. Baird upped their price objective on Alto Neuroscience from $22.00 to $41.00 and gave the company an “outperform” rating in a research note on Wednesday, March 18th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Alto Neuroscience Price Performance

Shares of ANRO opened at $21.57 on Thursday. The company has a market cap of $688.95 million, a price-to-earnings ratio of -9.89 and a beta of 2.01. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $25.17. The company’s fifty day simple moving average is $19.27 and its 200 day simple moving average is $14.88. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.11. On average, research analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC grew its position in shares of Alto Neuroscience by 1,048.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the last quarter. 683 Capital Management LLC acquired a new stake in Alto Neuroscience during the 4th quarter worth approximately $1,153,000. Artia Global Partners LP bought a new stake in Alto Neuroscience in the 4th quarter valued at $520,000. Spruce Street Capital LP acquired a new position in Alto Neuroscience in the 4th quarter valued at $3,967,000. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Alto Neuroscience by 14,567.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after buying an additional 211,222 shares in the last quarter.

Trending Headlines about Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Several brokers reaffirmed buy/outperform views and high upside potential — HC Wainwright kept a Buy and a $50 price target (large upside vs. current price). Article Title
• Positive Sentiment: Chardan Capital reaffirmed a Buy with a $30 target, signaling continued analyst conviction despite the trial miss. Article Title
• Positive Sentiment: JonesTrading kept a Buy rating while trimming its target from $49 to $44 — still implying substantial upside from current levels. Article Title
• Positive Sentiment: Robert W. Baird cut its target to $38 but left an Outperform rating — another signal that some analysts view the selloff as a buying opportunity. Article Title
• Neutral Sentiment: Wedbush trimmed its target to $21 and moved to a Neutral rating, reflecting a more cautious stance but only a small target cut vs. price. Article Title
• Neutral Sentiment: Company fundamentals: recent quarter slightly beat EPS expectations, Alto has a market cap near $689M, high liquidity metrics (current/quick ratio ~15.7) and high beta (~2.0) — factors that increase volatility but limit near-term solvency concerns.
• Negative Sentiment: Trial failure: Alto’s schizophrenia study missed its primary endpoint; that clinical setback is the primary driver of selling pressure and re-pricing. Article Title
• Negative Sentiment: Market reaction/coverage: multiple headlines highlight a sharp drop and pre-market weakness after the study news, amplifying volatility and headline-driven flows. Article Title
• Negative Sentiment: Sentiment hit from coverage calling the result a “shocking miss,” which can accelerate short-term selling and make recovery dependent on management commentary, further data, or new catalysts. Article Title

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.